Novartis
SMI Gains 0.7%, Defensive Stocks Offset AI Selloff as Oil Pushes Above $107
The Swiss benchmark index recovered part of last week's losses thanks to Roche, Novartis and Nestlé, while AI-linked tech names and building-material stocks fell on rising energy costs and Fed rate-hike expectations.
EU Approves Roche’s Susvimo for Neovascular AMD Treatment
The European Commission has granted marketing authorization for Roche’s implant-based Susvimo, marking the first continuous-delivery option for neovascular age-related macular degeneration.
Eurozone equities rise on oil price drop, KI optimism
European markets advanced Monday on lower crude prices and diplomatic hopes for Middle East stability, with tech stocks leading gains amid US-China KI talks.
Swiss Stocks rebound early week; Roche, Novartis lead, ABB and tech drag
The SMI rose 0.6% to 13,854 in a first countermove after last week's >4% slide. Pharmaceutical giants led gains while AI-linked and construction-materials names faced pressure from rising Brent crude above $107.
SMI Reverses to Loss as Novartis Rises, Alcon Drags; Oil Holds Above $100
The Swiss benchmark reversed an early gain to trade 0.2% lower, weighed by geopolitical risk and oil prices over $100. Novartis climbed 1.2% while Alcon lagged.
US Futures Rise as SMI Falls; Nestlé Dips on Russia Asset Seizure
S&P 500 and Nasdaq futures advance ahead of US open, while Switzerland's SMI drops 0.2% — Nestlé falls over temporary Russian control loss and Swisscom is set for index replacement.
Dax Flat as Oil Nears $100; Fresenius Leads Gainers, Infineon Slumps
The Dax stalled near 26,008 as Brent crude approached $100 a barrel on Middle East tensions. Fresenius led Dax gainers while Infineon and Novartis weighed on European indexes.
SMI closes with biggest daily loss since March; Nestlé, Richemont hit three-month lows
Swiss Market Index (SMI) suffered a significant decline, with Nestlé and Richemont reaching three-month lows amid rising oil prices and inflation concerns. DocMorris surged on new bond issuance plans.
EuroStoxx 50 rises slightly amid KI energy tensions
Swiss SMI weighed down by Novartis; global KI demand strains power grids and fuels market speculation on energy sector opportunities.
SMI Falls Below 14,000 as Oil Hits $100; Meta and Chime Lead Gainers
Switzerland's SMI slipped below 14,000 for the first time since mid-June on rising oil and inflation fears. Meta rose around 5% ahead of its AI agent launch, while Chime jumped 11% on a $590 million bank acquisition.
Swiss SMI falls below 14,000 as Brent oil hits $100
Switzerland's benchmark index slipped to its lowest level since mid-June amid oil-driven inflation worries, while luxury, construction and pharma stocks diverged.
Swiss shares fall as SMI slips below 14,000; DocMorris jumps on bond
SMI trades below 14,000 after weak US cues and high energy prices; Novartis lag after downgrade, luxury names fall, DocMorris rises on 100m CHF convertible.
Swiss stocks fall as oil pressure hits UBS, Richemont; Adecco, Barry Callebaut rise
Swiss shares slipped midweek on oil prices and US weakness, with Novartis, UBS and Richemont under pressure while Adecco, DocMorris and Barry Callebaut moved sharply.
Swiss equities open lower as SMI falls, Novartis under pressure
The Swiss Market Index drops 0.6% to 13,979 points, with only three SMI stocks gaining. Novartis faces renewed pressure, while Adecco and Barry Callebaut perform well.
Wall Street Opens Lower as Oil Surge Weighs; Nasdaq Edges Up on AI Stocks
Dow fell ~1% to 52,885 and S&P 500 dropped 0.4% to 7,690 on rising oil prices ahead of an ECB rate move; Nasdaq 100 gained 0.1% to 29,578 as AI-related shares offset weakness.
European Stocks Close Mixed; Novartis Slump Drag on Swiss SMI
The EuroStoxx 50 edged higher while the Swiss SMI fell 1.55% weighed down by Novartis, as investors waited on the ECB rate decision and Brent crude neared $100 a barrel.
European stocks little changed ahead of ECB and US inflation data
EuroStoxx 50 rose 0.17% to 6,403.99 as investors awaited Thursday's ECB decision and Friday's US inflation print, while oil shares gained on Gulf tensions.
SMI closes at session low as Novartis posts biggest daily loss ever
The Swiss benchmark fell 1.55% to 14,047, dragged by Novartis (-10.9%) after a Phase III study failure. UBS rose to a 19-year high above 45 francs.
US stocks fall as oil nears $100; Novartis posts steep loss
US indices slipped on higher oil prices and rate-hike concerns, while Novartis fell 9.8% after another trial disappointment and the SMI stayed near its low.
Novartis plunges as oil and rate worries push US and Swiss stocks lower
Novartis fell more than 9% after a phase-III miss, dragging the SMI lower as US stocks slipped on rising oil prices and rate-hike expectations.
US Markets Slide as Oil Hits $98; Novartis Plunges Toward Record Loss
Brent crude climbs toward $100 on Middle East tensions, weighing on Wall Street and Switzerland's SMI. Novartis falls nearly 10% after Phase III trial miss, wiping out roughly CHF 24 billion in market value.
US Markets Mixed After Holiday; Oil Weighs on Sentiment as Novartis Plunges
Dow futures sink 0.8% as Brent crude approaches $100; Novartis shares tumble over 9% after second clinical miss hits Swiss index.
US Stocks Expected to Open Mixed After Holiday; Oil Prices Pressuring Sentiment; SMI Continues Decline; Novartis Targets Record Daily Loss
US stock indices show slight movements before market open; oil prices rise, fueling concerns over rising interest rates; Swiss Market Index (SMI) continues to fall; Novartis shares plunge, potentially setting a record daily loss.
Novartis trial miss drags Swiss SMI lower; Nestlé, Ascom gain
Novartis shares fell nearly 10% after Del-desiran missed a Phase III endpoint, pulling the SMI lower while Nestlé, Sandoz and Ascom gained and Brent approached $100.